89bio

89bio Interest Expense

Delisted

The Interest Expense of 89bio (ETNB) as of Nov 8, 2026 is 19.77 M USD. In the previous year, Interest Expense was 14.08 M USD — a change of 40.38% (higher).

Interest Expense

19.77 MUSD

YoY

40.38%

Last updated:

Interest Expense of 89bio is 2024 19.77 M USD. Interest Expense of 89bio was 2023 14.08 M USD. It decreases by 40.38% higher compared to the previous year.

The 89bio Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2021
-530,000.00 USD
Jan 1, 2022
240,000.00 USD
Jan 1, 2023
14.08 M USD
Jan 1, 2024
19.77 M USD
The 89bio Interest Expense history
YEARInterest ExpenseYoY
19.77 MUSD+40.38%
14.08 MUSD+5,767.50%
240,000.00USD-145.28%
-530,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

89bio Stock analysis

What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California. 89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry. 89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism. The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body. In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion. Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 89bio stock

Interest Expense of 89bio is 19.77 M USD in 2024.

Interest Expense of 89bio changed from 14.08 M USD to 19.77 M USD, representing a 40.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense 89bio since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's 89bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — 89bio

All Key Metrics — 89bio